Cargando…

497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial

BACKGROUND: There remains a need for pre-exposure prophylaxis against SARS-CoV-2 infection in vulnerable patients in whom response to vaccination is often sub-optimal. The PROTECT-V platform trial is testing pre-exposure prophylactic interventions for COVID-19 in vulnerable patient populations: tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dosanjh, Davinder, Qian, Wendi, Dowling, Francis, Crowley, Louise, Chen-Xu, Michael, Smith, Rona M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679160/ http://dx.doi.org/10.1093/ofid/ofad500.566

Ejemplares similares

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
por: Totschnig, David, et al.
Publicado: (2022)

PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
por: Humphrey, Toby J. L., et al.
Publicado: (2023)

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
por: Gonzalez-Bocco, Isabel H., et al.
Publicado: (2023)

1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
por: Agostini, Maria L, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection
por: Weber, Sven C., et al.
Publicado: (2022)

Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark
por: Rasmussen, Line Dahlerup, et al.
Publicado: (2023)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
por: Rockett, Rebecca, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
por: Huygens, Sammy, et al.
Publicado: (2022)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial
por: Shapiro, Adrienne E, et al.
Publicado: (2023)

517. Safety and Tolerability of Intramuscular (IM) Sotrovimab 500 mg Administered at Different Injection Sites: Results from the Phase I COSMIC Study
por: Moore, Jennifer, et al.
Publicado: (2023)

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab
por: Magnus, Clara Luzia, et al.
Publicado: (2022)

Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients
por: Villanego, Florentino, et al.
Publicado: (2022)

In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys
por: Aweda, Tolulope A., et al.
Publicado: (2022)

Examination of Common Coronavirus Antibodies in SARS-CoV-2-Infected and Uninfected Participants in a Household Transmission Investigation
por: Stumpf, Megan M, et al.
Publicado: (2022)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
por: Zaqout, Ahmed, et al.
Publicado: (2022)

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
por: Kreye, Jakob, et al.
Publicado: (2023)

Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines
por: Aschauer, Constantin, et al.
Publicado: (2023)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

SARS-CoV-2 in immunocompromised individuals
por: DeWolf, Susan, et al.
Publicado: (2022)

Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants
por: Peterhoff, David, et al.
Publicado: (2022)

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
por: Cheng, Mindy M., et al.
Publicado: (2023)

Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
por: Woo, Marcel S., et al.
Publicado: (2022)

Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS
por: Adachi, Eisuke, et al.
Publicado: (2022)

SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses
por: Mazzetti, Paola, et al.
Publicado: (2023)

Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab
por: Palomino-Cabrera, Rosalía, et al.
Publicado: (2023)

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)

HPyV6 and HPyV7 in urine from immunocompromised patients
por: Prezioso, Carla, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in the immunocompromised host
por: Connolly, Caoilfhionn M., et al.
Publicado: (2022)

Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2
por: Di Chiara, Costanza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bdfntn3k8idj71s2ic47j29psd